Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
- PMID: 29599078
- DOI: 10.1016/S2468-1253(18)30056-6
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Abstract
Background: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment.
Methods: In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden.
Findings: We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3·9% (95% uncertainty interval [UI] 3·4-4·6), corresponding to 291 992 000 (251 513 000-341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4·8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1·8 (1·6-2·2) million infections were in children aged 5 years, with a prevalence of 1·4% (1·2-1·6). We estimated that 87% of infants had received the three-dose HBV vaccination in the first year of life, 46% had received timely birth-dose vaccination, and 13% had received hepatitis B immunoglobulin along with the full vaccination regimen. Less than 1% of mothers with a high viral load had received antiviral therapy to reduce mother-to-child transmission.
Interpretation: Our estimate of HBV prevalence in 2016 differs from previous studies, potentially because we took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time. Although some regions are well on their way to meeting prophylaxis and prevalence targets, all regions must substantially scale-up access to diagnosis and treatment to meet the global targets.
Funding: John C Martin Foundation.
Copyright �� 2018 Elsevier Ltd. All rights reserved.
Comment in
-
Delineating the global challenges of hepatitis B virus infection.Lancet Gastroenterol Hepatol. 2018 Jun;3(6):372-373. doi: 10.1016/S2468-1253(18)30093-1. Epub 2018 Mar 27. Lancet Gastroenterol Hepatol. 2018. PMID: 29599077 No abstract available.
-
Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission.Lancet Gastroenterol Hepatol. 2018 Sep;3(9):598-599. doi: 10.1016/S2468-1253(18)30198-5. Epub 2018 Aug 8. Lancet Gastroenterol Hepatol. 2018. PMID: 30102179 No abstract available.
-
Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission.Lancet Gastroenterol Hepatol. 2018 Sep;3(9):598. doi: 10.1016/S2468-1253(18)30176-6. Epub 2018 Aug 8. Lancet Gastroenterol Hepatol. 2018. PMID: 30102180 No abstract available.
-
Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission - Authors' reply.Lancet Gastroenterol Hepatol. 2018 Sep;3(9):599. doi: 10.1016/S2468-1253(18)30199-7. Epub 2018 Aug 8. Lancet Gastroenterol Hepatol. 2018. PMID: 30102181 No abstract available.
Similar articles
-
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27. Lancet Gastroenterol Hepatol. 2023. PMID: 37517414
-
How to control highly endemic hepatitis B in Asia.Liver Int. 2018 Feb;38 Suppl 1:122-125. doi: 10.1111/liv.13625. Liver Int. 2018. PMID: 29427490 Review.
-
#38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission.Am J Obstet Gynecol. 2016 Jan;214(1):6-14. doi: 10.1016/j.ajog.2015.09.100. Epub 2015 Oct 8. Am J Obstet Gynecol. 2016. PMID: 26454123 Review.
-
Prevalence of HBV and HCV infections, Bhutan, 2017: Progress and next steps.BMC Infect Dis. 2020 Jul 8;20(1):485. doi: 10.1186/s12879-020-05176-3. BMC Infect Dis. 2020. PMID: 32641006 Free PMC article.
-
Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study.Lancet Gastroenterol Hepatol. 2023 Jul;8(7):635-645. doi: 10.1016/S2468-1253(23)00074-2. Epub 2023 May 5. Lancet Gastroenterol Hepatol. 2023. PMID: 37150181
Cited by
-
Pregnant women with chronic hepatitis B virus infection at the assessment of tenofovir disoproxil fumarate prescription: Baseline characteristics of a prospective cohort study in Vietnam.IJID Reg. 2024 May 7;11:100375. doi: 10.1016/j.ijregi.2024.100375. eCollection 2024 Jun. IJID Reg. 2024. PMID: 38827634 Free PMC article.
-
Knowledge and Testing of Hepatitis B Virus Infection and Vaccination Awareness among University Students in Kumasi, Ghana: A Cross-Sectional Study.Scientifica (Cairo). 2024 May 20;2024:4052837. doi: 10.1155/2024/4052837. eCollection 2024. Scientifica (Cairo). 2024. PMID: 38803356 Free PMC article.
-
Roles Played by DOCK11, a Guanine Nucleotide Exchange Factor, in HBV Entry and Persistence in Hepatocytes.Viruses. 2024 May 8;16(5):745. doi: 10.3390/v16050745. Viruses. 2024. PMID: 38793626 Free PMC article. Review.
-
Hepatitis B Virus Infection: A Mini Review.Viruses. 2024 May 3;16(5):724. doi: 10.3390/v16050724. Viruses. 2024. PMID: 38793606 Free PMC article. Review.
-
Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.Medicine (Baltimore). 2024 May 17;103(20):e37953. doi: 10.1097/MD.0000000000037953. Medicine (Baltimore). 2024. PMID: 38758884 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical